Nevro Corp. (NYSE:NVRO) Receives Consensus Recommendation of "Hold" from Brokerages

Nevro Corp. (NYSE:NVRO - Get Free Report) has been assigned an average recommendation of "Hold" from the thirteen brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $21.54.

NVRO has been the topic of several recent research reports. Mizuho reduced their price objective on Nevro from $20.00 to $16.00 and set a "neutral" rating on the stock in a research report on Thursday. Robert W. Baird decreased their target price on shares of Nevro from $23.00 to $19.00 and set a "neutral" rating on the stock in a research report on Thursday, February 22nd. Citigroup cut their price target on shares of Nevro from $18.00 to $16.00 and set a "neutral" rating for the company in a research report on Wednesday, April 3rd. StockNews.com upgraded Nevro from a "sell" rating to a "hold" rating in a report on Friday, March 1st. Finally, Canaccord Genuity Group reissued a "hold" rating and issued a $23.00 target price on shares of Nevro in a research note on Thursday, December 21st.

Nevro Price Performance

NVRO stock traded up $0.11 during midday trading on Friday, reaching $13.23. The company had a trading volume of 472,131 shares, compared to its average volume of 478,582. The firm has a 50-day moving average price of $14.96 and a 200-day moving average price of $17.06. The company has a market capitalization of $481.57 million, a P/E ratio of -5.17 and a beta of 0.89. Nevro has a 1 year low of $12.34 and a 1 year high of $39.67. The company has a debt-to-equity ratio of 0.72, a current ratio of 6.37 and a quick ratio of 4.94.

Nevro (NYSE:NVRO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.35. The company had revenue of $116.18 million during the quarter, compared to the consensus estimate of $115.93 million. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. On average, research analysts anticipate that Nevro will post -2.53 earnings per share for the current fiscal year.

Institutional Trading of Nevro

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP boosted its position in Nevro by 174.3% during the 2nd quarter. Quarry LP now owns 1,012 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 643 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Nevro by 26.8% during the third quarter. Tower Research Capital LLC TRC now owns 3,162 shares of the medical equipment provider's stock valued at $61,000 after purchasing an additional 668 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Nevro by 1.6% during the second quarter. California State Teachers Retirement System now owns 43,215 shares of the medical equipment provider's stock valued at $1,099,000 after purchasing an additional 670 shares in the last quarter. Assetmark Inc. grew its stake in Nevro by 30.4% in the fourth quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider's stock worth $67,000 after purchasing an additional 730 shares during the period. Finally, Rhumbline Advisers raised its holdings in Nevro by 1.6% in the first quarter. Rhumbline Advisers now owns 47,080 shares of the medical equipment provider's stock worth $1,702,000 after purchasing an additional 744 shares in the last quarter. Hedge funds and other institutional investors own 95.52% of the company's stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.